Frontiers in Medicine最新文献

{"title":"Eliglustat and cardiac comorbidities in Gaucher disease: a pharmacogenomic approach to safety and efficacy.","authors":"Noor Ul Ain, Armaan Saith, Audrey Ruan, Ruhua Yang, Aaron Burton, Pramod K Mistry","doi":"10.3389/fmed.2025.1535099","DOIUrl":"10.3389/fmed.2025.1535099","url":null,"abstract":"<p><strong>Introduction: </strong>Gaucher disease (GD), a lysosomal storage disorder, results from the accumulation of glycosphingolipids due to deficient lysosomal glucocerebrosidase activity. This pathological accumulation triggers immune activation, which paradoxically induces UDPglucose ceramide glucosyltransferase (UGCG), further exacerbating the metabolic defect. Eliglustat, a highly specific inhibitor of UGCG, functions as a substrate reduction therapy (SRT) and has demonstrated efficacy in reversing GD manifestations in clinical trials and real-world settings. Despite its established safety profile, preclinical studies have shown that supratherapeutic concentrations of eliglustat can inhibit ion channels involved in cardiac electrophysiology. However, pharmacogenomic-guided dosing ensures therapeutic efficacy while maintaining a wide safety margin, minimizing such risks. Nevertheless, lingering concerns regarding cardiac safety have persisted, particularly in patients with preexisting cardiac comorbidities.</p><p><strong>Methods: </strong>We report a single-center experience of eliglustat use in 13 patients with type 1 Gaucher disease (GD1) and concurrent cardiac comorbidities. Patients underwent standard cardiac evaluations, including electrocardiogram (EKG) with QTc interval assessment and echocardiogram. Eliglustat dosing was guided by CYP2D6 metabolizer status, and potential drug-drug interactions (DDIs) were carefully monitored.</p><p><strong>Results: </strong>Cardiac comorbidities included prior myocardial infarction (<i>n</i> = 2), aortic stenosis (<i>n</i> = 2), atrial fibrillation (<i>n</i> = 2), Wolff-Parkinson-White syndrome (<i>n</i> = 1), pericarditis (<i>n</i> = 1), premature ventricular complexes (<i>n</i> = 2), severe pulmonary arterial hypertension with right heart strain (<i>n</i> = 1), mitral annular calcification with diastolic dysfunction (<i>n</i> = 1), and mildly prolonged QTc interval (<i>n</i> = 1). No patients experienced arrhythmia, QTc prolongation, or arrhythmia-related symptoms. Treatment discontinuation was not required. All patients achieved expected therapeutic outcomes, as evidenced by serial reductions in glucosylsphingosine (GlcSph) levels and other disease indicators.</p><p><strong>Conclusion: </strong>This study represents the first real-world clinical evidence evaluating Eliglustat's cardiac safety in a high-risk GD1 population. Unlike prior theoretical concerns derived from <i>in vitro</i> ion channel studies, our findings demonstrate that Eliglustat does not induce clinically significant cardiac events when administered according to pharmacogenomic guidelines. The misinformation regarding Eliglustat's cardiotoxicity, largely driven by speculative interpretations rather than clinical data, is effectively countered by our findings, which show no significant QT prolongation or arrhythmias over a median treatment duration of 8 years.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1535099"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of potential hub genes and drugs in septic kidney injury: a bioinformatic analysis with preliminary experimental validation.","authors":"Shujun Sun, Yuanyuan Ding, Dong Yang, Jiwei Shen, Tianhao Zhang, Guobin Song, Xiangdong Chen, Yun Lin, Rui Chen","doi":"10.3389/fmed.2025.1502189","DOIUrl":"10.3389/fmed.2025.1502189","url":null,"abstract":"<p><strong>Background: </strong>Sepsis-associated kidney injury (SAKI) is a prevalent complication in intensive care unit (ICU) patients with sepsis. Diagnosis currently relies on clinical assessment, urine output, and serum creatinine levels, yet effective clinical treatments remain scarce. Our objectives are to explore prospective, targeted medications for the treatment of septic kidney injury and to employ bioinformatics to identify key genes and pathways that may be implicated in the pathogenesis of SAKI.</p><p><strong>Methods: </strong>We utilized the GEO database for differential gene screening. Related genes of septic kidney injury were identified through Pubmed2Ensembl, followed by annotation and visualization of gene ontology biological processes and KEGG pathways using DAVID. Protein-protein interactions were analyzed with the STRING database, and hub genes were identified using Cytoscape software. Candidate genes were further validated through Metascape. The CTD database was employed to uncover the relationship between hub genes and acute kidney injury (AKI). CIBERSORT was applied to evaluate the infiltration of immune cells and their association with hub genes. Hub genes were experimentally verified through qPCR detection. Lastly, the Drug-Gene Interaction Database (DGIdb) was utilized to identify drug-gene interactions.</p><p><strong>Results: </strong>Six genes, including TNF, CXCL8, IL-6, IL-1β, IL-2, and IL-10, were associated with three major signaling pathways: the COVID-19 adverse outcome pathway, an overview of pro-inflammatory and pro-fibrotic mediators, and the interleukin-10 signaling pathway. Additionally, 12 targeted drugs were identified as potential therapeutic agents.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1502189"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study.","authors":"Enrico Costa, Vittorio Del Grosso, Bernadette Cappello, Armando A Genazzani, Benedikt Huttner, Hubert G M Leufkens, Nicola Magrini, Francesco Nonino, Veronika J Wirtz, Hendrika A van den Ham, Lorenzo Moja","doi":"10.3389/fmed.2025.1517020","DOIUrl":"10.3389/fmed.2025.1517020","url":null,"abstract":"<p><strong>Background: </strong>The WHO Model List of Essential Medicines (EML) includes those medicines that offer the best health payback for individuals and health systems. It serves as a guide for countries to develop and update national EMLs. The implementation of essential medicines policies is therefore mostly oriented to medicines on the EML. However, medicines evaluated and not recommended for inclusion in the EML also have relevant implications for development of efficient medicine policies. This study analyzed the characteristics, frequencies, and reasons for applications for medicines proposed for inclusion in the WHO EML not being recommended.</p><p><strong>Methods: </strong>Assessment of the recommendations for all medicines proposed for inclusion in the WHO EML in reports of the Expert Committee on Selection and Use of Essential Medicines in the WHO Technical Reports Series from 2002 to 2023. We collected key information from EML applications including active substance, therapeutic indication, orphan status, applicant, and reasons for negative recommendations. Logistic univariate and multivariate regression analyses assessed predictive characteristics for applications with negative recommendations.</p><p><strong>Results: </strong>A total of 359 applications for addition of new medicines to the EML were submitted: 211 (58.8%) received a positive recommendation. Among the 148 (41.2%) applications with a negative recommendation, the most prevalent reasons for not recommending were quality of clinical evidence (62.1%) and economic criteria (33.1%). Concerns about capacity to implement the new medicines in health care systems or requiring specialized expertise increased over time. Applications submitted by pharmaceutical companies, individuals not affiliated with scientific societies or non-governmental organizations, and academia were more prone to receiving a negative recommendation.</p><p><strong>Discussion: </strong>An appreciable proportion of applications for addition of new medicines to the EML are not recommended. Over time, low or limited quality of clinical evidence was a consistent explanatory reason leading to non-recommending. Economic considerations and feasibility are emerging justifications for non-recommending.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1517020"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe adenovirus pneumonia complicated by acute respiratory distress syndrome in immunocompetent patients: a case report and literature review.","authors":"Lei Zhang, Yuxin Guo, Xudong Wang, Wei Gai, Lina Liu","doi":"10.3389/fmed.2025.1524783","DOIUrl":"10.3389/fmed.2025.1524783","url":null,"abstract":"<p><strong>Background: </strong>Human adenovirus (HAdV) is one of the most important pathogens detected in acute respiratory illness in pediatric and immunocompromised patients, but it is relatively rare to develop severe pneumonia in immunocompetent patients. We analyzed the clinical features, as well as the diagnosis and treatment processes, to provide a reference for clinical practice.</p><p><strong>Case presentation: </strong>We report a case of severe pneumonia caused by HAdV, complicated by acute respiratory distress syndrome (ARDS), in an immunocompetent patient with no underlying conditions. Chest computed tomography (CT) revealed consolidation in the right lower lung. Conventional microbial tests were negative, but metagenomic next-generation sequencing (mNGS) identified a large number of HAdV sequences in blood and sputum. Together with the clinical symptoms, this confirmed the diagnosis of severe pneumonia caused by HAdV. The patient was discharged after timely treatment with cidofovir.</p><p><strong>Conclusion: </strong>In our study, we described a rare case of severe pneumonia caused by HAdV, complicated by ARDS, in an immunocompetent patient. mNGS proves to be an effective diagnostic tool for guiding treatment decisions.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1524783"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of case-based learning on critical thinking dispositions in Chinese nursing education: a systematic review and meta-analysis.","authors":"Yunlu Xiang, Dong Liu, Liang Liu, I-Chun Liu, Lanka Wu, Hao Fan","doi":"10.3389/fmed.2025.1452051","DOIUrl":"10.3389/fmed.2025.1452051","url":null,"abstract":"<p><strong>Background: </strong>Case-based learning (CBL) is recognized for its potential to enhance critical thinking in nursing education. This meta-analysis aimed to assess the impact of CBL alone or in combination with other methods on improving critical thinking dispositions among nursing students in China.</p><p><strong>Methods: </strong>A systematic search was conducted in databases including PubMed, Embase, Cochrane Library, CINAHL and China National Knowledge Infrastructure from inception of the databases through June 1, 2024. Studies that utilized the Chinese Version of Critical Thinking Dispositions Inventory (CTDI-CV) and compared CBL with traditional teaching methods were included. Random-effects models were used to pool the mean differences (MD) in critical thinking scores, and subgroup analyses were performed based on participant types and intervention methods.</p><p><strong>Results: </strong>Thirteen studies involving 1,396 participants were included. The pooled results indicated a significant improvement in critical thinking dispositions (MD = 26.39, 95% CI: 18.71 to 34.06). Subgroup analysis revealed that nursing interns and combinations of CBL with problem-based learning (PBL) reported higher improvements. Secondary outcomes showed significant gains in both theoretical knowledge and operational skills, with heterogeneity observed across studies (<i>I</i> ² > 79%). The Egger's test (<i>p</i> = 0.95) suggested no significant publication bias.</p><p><strong>Conclusion: </strong>CBL significantly enhances critical thinking among nursing students in China, particularly when integrated with PBL. Despite the observed heterogeneity, the findings support the incorporation of CBL into nursing curricula to foster critical analytical skills. Further research should explore the contextual factors that affect the variability in outcomes.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1452051"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cracking the code of HBV persistence: cutting-edge approaches to targeting cccDNA in chronic hepatitis B with or without pyogenic liver Abscesses.","authors":"Umar Saeed, Zahra Zahid Piracha, Mahmood Khan, Muhammad Nouman Tariq, Syed Shayan Gilani, Muhammad Raza, Rakshana Munusamy, Naveen Bose, Dilber Uzun Ozsahin, İlker Özşahin, Surya M Nauli","doi":"10.3389/fmed.2025.1504736","DOIUrl":"10.3389/fmed.2025.1504736","url":null,"abstract":"<p><p>Chronic Hepatitis B Virus (HBV) infection remains a formidable global health challenge, driving severe liver complications such as hepatocellular carcinoma (HCC) and pyogenic liver abscesses (PLA). At the core of HBV persistence lies covalently closed circular DNA (cccDNA), a viral reservoir that fuels ongoing infection despite antiviral treatments. This review highlights molecular mechanisms governing cccDNA formation, maintenance, and clearance, spotlighting innovative therapeutic strategies to disrupt this key viral element. We explore cutting-edge approaches, including epigenetic modulation to silence cccDNA, RNA interference (RNAi) for viral RNA degradation, and CRISPR/Cas genome editing to excise cccDNA directly. Additionally, emerging antiviral therapies and immunotherapies, such as therapeutic vaccines and immune checkpoint inhibitors, offer new avenues for enhanced treatment efficacy. Special attention is given to the clinical complexities of managing HBV in patients with co-morbid conditions like HCC and PLA, emphasizing the necessity of a multidisciplinary approach. The interplay between antibacterial and antiviral therapies in PLA-associated HBV cases is critically examined to prevent treatment antagonism, ensuring optimal patient outcomes. Advanced therapeutic strategies, including nucleos(t)ide analogs, interferon therapy, and novel genomic interventions, are explored in both isolated HBV infection and PLA co-infections. Personalized regimens remain pivotal in enhancing therapeutic efficacy and long-term disease control. Current review advocates for a shift toward precision medicine, highlighting the critical need for interdisciplinary collaboration to bridge molecular discoveries with clinical innovations. Ultimately, these advancements promise to revolutionize the management of chronic HBV, paving the way for potential cures and improved patient outcomes.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1504736"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of immune characteristic biomarkers and therapeutic targets in cuproptosis for rheumatoid arthritis by integrated bioinformatics analysis and single-cell RNA sequencing analysis.","authors":"Xianbin Li, Xueli Zhang, Tao Liu, Guodao Zhang, Dan Chen, Suxian Lin","doi":"10.3389/fmed.2025.1520400","DOIUrl":"10.3389/fmed.2025.1520400","url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disorder intricately liked with inflammation. Cuproptosis, an emerging type of cell death, has been implicated in the initiation and development of RA. However, the exact alterations in the expression and biological function of cuproptosis-related genes (CRGs) in RA remain poorly understood. Therefore, our study aims to elucidate the potential association between CRGs and RA, with the goal of identifying novel biomarkers for the treatment and prognosis of RA.</p><p><strong>Methods: </strong>In this study, we identified ten differentially expressed cuproptosis-related genes (DE-CRGs) between patients with RA and controls. Through comprehensive functional enrichment and protein-protein interaction (PPI) network analysis, we explored the functional roles of the DE-CRGs. Additionally, we investigated the correlation between DE-CRGs and immune infiltration, immune factors, diagnostic efficacy, and potential therapeutic drugs.</p><p><strong>Results: </strong>Leveraging single-cell RNA sequencing data, we conducted a detailed analysis to elucidate alterations in various cell clusters associated with RA. Our study unveiled a significant association between DE-CRGs and diverse biological functions, as well as potential drug candidates.</p><p><strong>Discussion: </strong>These findings provide crucial insights into the involvement of DE-CRGs in the pathogenesis of RA and shed light on potential therapeutic strategies.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1520400"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Pulmonary echinococcosis misdiagnosed as bronchogenic pulmonary cysts.","authors":"Qingcheng Yang, Lyubo Wang, Yuanlong Shi, Siyun Liu, Daoguang Fan, Bencheng Wu, Yi Duan, Chenjun Xin, Lincan Duan","doi":"10.3389/fmed.2025.1533124","DOIUrl":"10.3389/fmed.2025.1533124","url":null,"abstract":"<p><p>Echinococcosis, also known as hydatid disease, is a zoonotic parasitic infection that poses a significant risk to human health. This article delineates the diagnostic and therapeutic course of a patient afflicted with pulmonary echinococcosis who was admitted to the Department of Thoracic Surgery II at Yunnan Cancer Hospital in April 2024. The patient exhibited a history of extensive exposure to livestock and a penchant for consuming undercooked meat. Prior to undergoing surgical intervention, the patient was initially diagnosed with bronchogenic pulmonary cyst. However, subsequent pathological examination revealed a diagnosis of pulmonary echinococcosis. The rarity of the disease and the paucity of experience in diagnosis and treatment rendered the patient's case a valuable opportunity to elucidate the diagnostic and therapeutic journey. This report aims to provide a comprehensive reference for the accurate identification and treatment of pulmonary echinococcosis in future clinical practice.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1533124"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Gut microbiota and gastrointestinal disorders, volume II.","authors":"Abbas Yadegar, Aryan Salahi-Niri, Yan-Dong Wang, Javier Ochoa-Repáraz","doi":"10.3389/fmed.2025.1576152","DOIUrl":"10.3389/fmed.2025.1576152","url":null,"abstract":"","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1576152"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lamellar keratoplasty using acellular porcine corneal stroma for the treatment of corneal ulcers.","authors":"Yiming Hu, Lan Zhang, Lei Wu, Yao Zhu, Li Wu, Chenye Li, Youyang Ruan, Yunwei Hu, Feifei Wang, Zhirong Lin, Qifang Jin","doi":"10.3389/fmed.2025.1534210","DOIUrl":"10.3389/fmed.2025.1534210","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to investigate the efficacy and safety of acellular porcine corneal stroma (APCS) for lamellar keratoplasty in the treatment of corneal ulcers.</p><p><strong>Methods: </strong>A total of 14 patients (14 eyes) diagnosed with corneal ulcers who underwent lamellar keratoplasty using acellular porcine corneal stroma at the Second Affiliated Hospital of Nanchang University between June 2016 and May 2017 were recruited and followed up for at least 12 months. Postoperative visual acuity, epithelial recovery, graft transparency, the recurrence rate of corneal ulcers, the rate of graft rejection, corneal neovascularization, graft infection, secondary glaucoma, and graft melting were examined and analyzed.</p><p><strong>Results: </strong>All 14 patients (100%) who underwent lamellar keratoplasty using acellular porcine corneal stroma successfully preserved the structure of their eyeballs. The visual acuity improved in 11 patients (78.5%). Graft rejection occurred in one patient (7.1%), while two patients (14.3%) developed recurrent corneal ulcers. Corneal vessel ingrowth was observed in seven patients (50%), and one patient (7.1%) developed pseudopterygium. The average time for complete epithelial recovery was 3-7 days.</p><p><strong>Conclusion: </strong>Lamellar keratoplasty using acellular porcine corneal stroma is an effective surgical alternative for the treatment of corneal ulcers.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1534210"},"PeriodicalIF":3.1,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}